Correction to: Evaluation of drug-drug interactions of pemigatinib in healthy participants

Tao Ji¹ · Kevin Rockich¹ · Noam Epstein^{1,2} · Heather Overholt¹ · Phillip Wang¹ · Xuejun Chen¹ · Naresh Punwani¹ · Swamy Yeleswaram¹

Published online: 26 August 2021

© Springer-Verlag GmbH Germany, part of Springer Nature 2021

Correction to: European Journal of Clinical Pharmacology
<https://doi.org/10.1007/s00228-021-03184-z>

An error occurred in the abstract of the manuscript published online ahead of print. The order of “AUC” and “C_{max}” was erroneously reversed in the following sentence in the abstract Results section: “There was a 35% and 8% decrease in pemigatinib AUC and C_{max}, respectively, with esomeprazole...” This sentence should read “There was a 35% and 8% decrease in pemigatinib C_{max} and AUC, respectively, with esomeprazole...” The authors apologize for this error and any inconvenience caused.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The original article can be found online at <https://doi.org/10.1007/s00228-021-03184-z>.

✉ Tao Ji
tji@incyte.com

¹ Incyte Research Institute, 1801 Augustine Cut-off, Wilmington, DE 19803, USA

² GlaxoSmithKline, Collegeville, Philadelphia, PA, USA